Autolus Therapeutics (AUTL) Net Income towards Common Stockholders (2017 - 2025)

Autolus Therapeutics' Net Income towards Common Stockholders history spans 6 years, with the latest figure at -$90.3 million for Q4 2025.

  • For Q4 2025, Net Income towards Common Stockholders fell 227.22% year-over-year to -$90.3 million; the TTM value through Dec 2025 reached -$287.5 million, down 30.3%, while the annual FY2025 figure was -$287.5 million, 30.3% down from the prior year.
  • Net Income towards Common Stockholders reached -$90.3 million in Q4 2025 per AUTL's latest filing, down from -$79.1 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of -$27.0 million in Q4 2022 to a low of -$90.3 million in Q4 2025.
  • Average Net Income towards Common Stockholders over 4 years is -$54.1 million, with a median of -$46.9 million recorded in 2023.
  • Peak YoY movement for Net Income towards Common Stockholders: surged 64.23% in 2024, then tumbled 227.22% in 2025.
  • A 4-year view of Net Income towards Common Stockholders shows it stood at -$27.0 million in 2022, then plummeted by 186.04% to -$77.2 million in 2023, then soared by 64.23% to -$27.6 million in 2024, then crashed by 227.22% to -$90.3 million in 2025.
  • Per Business Quant, the three most recent readings for AUTL's Net Income towards Common Stockholders are -$90.3 million (Q4 2025), -$79.1 million (Q3 2025), and -$47.9 million (Q2 2025).